Clinical Trial: Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Prospective French Study on ACQUIred Haemophilia Treatment With Recombinant Factor VIIa (NovoSeven®) A Prospective Observational Study on the Use of NovoSeven® (

Brief Summary: This study is conducted in Europe. The aim of this prospective, observational study are to describe the different clinical practice and detailed haemostatic management of activated recombinant human factor VII (NovoSeven®) in patients with acquired haemophilia in France. The secondary aim is to assess the primary haemostasis disorder associated with the coagulation disorders, if available.

Detailed Summary:
Sponsor: Novo Nordisk A/S

Current Primary Outcome: Identification of decision criteria to treat patient with activated recombinant human factor VII [ Time Frame: Year 3 ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Number of patients with a control of bleeding [ Time Frame: Year 3 ]

Original Secondary Outcome: Same as current

Information By: Novo Nordisk A/S

Dates:
Date Received: January 26, 2011
Date Started: December 2010
Date Completion:
Last Updated: January 29, 2014
Last Verified: January 2014